Orserdu combinations show favorable safety profiles for ER+, HER2- metastatic breast cancer in phase Ib/II trials

Scientists uncover new approach for targeting aggressive breast cancer

A recent study from cancer researchers at the University of Alabama at Birmingham and Georgia State University has identified a new therapeutic target in quadruple-negative breast cancer, or QNBC, one of the deadliest and most aggressive treatment-resistant forms of breast cancer.

July 03, 2025

Vol.51 No.26

Clinical Roundup

Scientists wipe out aggressive brain cancer tumors by targeting cellular “motors”

A potential treatment for glioblastoma crafted by scientists at The Wertheim UF Scripps Institute renders the deadly brain cancer newly sensitive to both radiation and chemotherapy drugs, and blocks the cancer’s ability to invade other tissue, a new study shows.

July 03, 2025

Vol.51 No.26

Clinical Roundup

Rucaparib maintenance therapy demonstrates PFS benefit for HRD-negative and HRD-positive ovarian cancer

First-line rucaparib maintenance treatment provided a progression-free survival benefit vs placebo in newly diagnosed, advanced, high-grade ovarian cancer after front-line platinum-based chemotherapy.

June 27, 2025

Vol.51 No.25

Cancer Policy

FDA halts new clinical trials that export Americans’ cells to foreign labs in hostile countries

FDA has announced that the agency will begin immediately reviewing all new clinical trials that include shipping American citizens’ living cells to “China and other hostile countries for genetic engineering and subsequent infusion” back into American patients.

June 20, 2025

Vol.51 No.24

By Claire Marie Porter

In Brief

UNC Lineberger awarded up to $28M from ARPA-H to develop clinical trial for metastatic breast cancer

UNC Lineberger Comprehensive Cancer Center has been awarded up to $28 million by the Advanced Research Projects Agency for Health to lead the development of a next-generation clinical trial for breast cancer that has spread to other parts of the body.

June 20, 2025

Vol.51 No.24

Clinical Roundup

Study of retifanlimab in squamous cell carcinoma meets primary endpoint of PFS

Primary results from the phase III POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz), a humanized monoclonal antibody targeting programmed death receptor-1, in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer who have not been previously treated with systemic chemotherapy, were published in The Lancet.

June 20, 2025

Vol.51 No.24

Orserdu combinations show favorable safety profiles for ER+, HER2- metastatic breast cancer in phase Ib/II trials

YOU MAY BE INTERESTED IN

Scientists uncover new approach for targeting aggressive breast cancer

Scientists wipe out aggressive brain cancer tumors by targeting cellular “motors”

Rucaparib maintenance therapy demonstrates PFS benefit for HRD-negative and HRD-positive ovarian cancer

FDA halts new clinical trials that export Americans’ cells to foreign labs in hostile countries

UNC Lineberger awarded up to $28M from ARPA-H to develop clinical trial for metastatic breast cancer

Study of retifanlimab in squamous cell carcinoma meets primary endpoint of PFS

Renew today!

Subscriber content

Never miss an issue!

Login